ArticleThe American journal of pathology2009
Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis.
Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 90 citations in OpenAlex.
- Evasins: Biology and Therapeutic Potential of Broad-Spectrum Chemokine Inhibitors.Basic & clinical pharmacology & toxicology · 2026Review
- Development of chemokine network inhibitors using combinatorial saturation mutagenesis.Communications biology · 2025Article
- Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view.Frontiers in allergy · 2025Article
- Diets Supplemented with Probiotics Improve the Performance of Broilers Exposed to Heat Stress from 15 Days of Age.Probiotics and antimicrobial proteins · 2023Article
- Article
- Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.Probiotics and antimicrobial proteins · 2022Article
- The binding and specificity of chemokine binding proteins, through the lens of experiment and computation.Biomedical journal · 2022Review
- Structure-guided engineering of tick evasins for targeting chemokines in inflammatory diseases.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- RecombinantFrontiers in microbiology · 2022Article
- Lack of protective effect of CCR3 blockade during experimental colitis may be related to CCR3 expression by colonic Tregs.Clinical and translational medicine · 2021Article
- Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.Annual review of immunology · 2021Article
- NLRP6-associated host microbiota composition impacts in the intestinal barrier to systemic dissemination of Brucella abortus.PLoS neglected tropical diseases · 2021Article
- AeMOPE-1, a Novel Salivary Peptide FromFrontiers in immunology · 2021Article
- Characterization and Analysis of the Temporal and Spatial Dynamic of Several Enteritis Modeling Methodologies.Frontiers in immunology · 2021Article
- SlpB Protein Enhances the Probiotic Potential ofFrontiers in pharmacology · 2021Article
- Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?Frontiers in immunology · 2021Review
- Semisynthesis of an evasin from tick saliva reveals a critical role of tyrosine sulfation for chemokine binding and inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The Role of ST2 Receptor in the Regulation ofPathogens (Basel, Switzerland) · 2020Article
- The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Evasins: Tick Salivary Proteins that Inhibit Mammalian Chemokines.Trends in biochemical sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophils are multifunctional leukocytes implicated in numerous inflammatory diseases. The present study was conducted to clarify the precise role of eosinophils in the development of colitis by using eosinophil-depleted mice and a novel chemokine-binding protein that neutralizes CCL11 action. Colitis was induced by administration of dextran sodium sulfate (DSS) to wild-type and eosinophil-deficient DeltadblGATA-1 mice. Accumulation of eosinophils in the gut of mice given DSS paralleled worsening of clinical score and weight loss. In response to DSS, DeltadblGATA-1 mice showed virtual absence of eosinophil recruitment, amelioration of clinical score, weight loss, and tissue destruction, and no lethality. There was a decrease in CXCL1 and CCL3 production and decreased neutrophil influx in the intestine of DeltadblGATA-1 mice. Transfer of bone marrow cells from wild-type mice reconstituted disease manifestation in DSS-treated DeltadblGATA-1 mice, and levels of CCL11 were increased after DSS treatment and localized to inflammatory cells. Treatment with the chemokine-binding protein evasin-4 at a dose that prevented the function of CCL11 greatly ameliorated clinical score, weight loss, overall tissue destruction, and death rates. In conclusion, the influx of eosinophils is critical for the induction of colitis by DSS. Treatment with a novel chemokine-binding protein decreased eosinophil influx and greatly ameliorated colitis, suggesting that strategies that interfere with the recruitment of eosinophils may be useful as therapy for colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.